Silexion Therapeutics Corp Share Holder Equity 2021-2024 | SLXN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Silexion Therapeutics Corp share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Silexion Therapeutics Corp share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$180.1B
Regeneron Pharmaceuticals (REGN)	$127.1B
Vertex Pharmaceuticals (VRTX)	$126.3B
Gilead Sciences (GILD)	$103.5B
Bristol Myers Squibb (BMY)	$101.3B
CSL (CSLLY)	$97.4B
GSK (GSK)	$90.3B
Alnylam Pharmaceuticals (ALNY)	$34.7B
Argenex SE (ARGX)	$32.2B
BioNTech SE (BNTX)	$29.4B
Biogen (BIIB)	$29.1B
Moderna (MRNA)	$26.6B
Illumina (ILMN)	$20.6B
BeiGene (BGNE)	$19.1B
Genmab (GMAB)	$17.6B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$12.8B
Incyte (INCY)	$12.8B
Vaxcyte (PCVX)	$12.8B
Insmed (INSM)	$12.6B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.6B
Legend Biotech (LEGN)	$9.4B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.1B
Halozyme Therapeutics (HALO)	$8B
Intra-Cellular Therapies (ITCI)	$8B
Repligen (RGEN)	$7.8B